---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-251917"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:34:28.817763+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology prices $55M public offering of common stock and pre-funded warrants

## Summary
- Priced public offering of 7,370,690 shares at $6.38/share and pre-funded warrants for 1,250,000 shares at $6.379/warrant.
- Gross proceeds expected ~$55M before underwriting discounts; offering to close Oct 10, 2023.
- Net proceeds to fund evorpacept clinical development including ASPEN-06 trial, working capital.
- Underwriters granted 30-day option to purchase up to 1,293,103 additional shares.

## SEC filing metadata
- accession: 0001193125-23-251917
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312523251917/0001193125-23-251917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312523251917/d534693d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-251917
- JSON: https://secwatch.observer/filing/0001193125-23-251917.json
- Plain text: https://secwatch.observer/filing/0001193125-23-251917.txt

## Key facts
- Material Agreements
  ALX ONCOLOGY HOLDINGS INC entered into Underwriting Agreement with Piper Sandler & Co. and Cantor Fitzgerald & Co. valued at approximately $55.0 million (effective 2023-10-04).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Piper Sandler & Co. and Cantor Fitzgerald & Co.
  - Value: approximately $55.0 million
  - Effective: 2023-10-04
  source text: On October 4, 2023, ALX Oncology Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 7,370,690 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $6.38 per share (the “Underwritten Shares”) and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,250,000 shares of the Company’s common stock at a price to the public of $6.379 per Pre-Funded Warrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000119312523251917/0001193125-23-251917-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.